Precision medicine: how multiomics will shape the future of inflammatory bowel disease?

Nienke Z. Borren, Ashwin N. Ananthakrishnan*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

1 Citation (Scopus)

Abstract

Purpose of review In this article, we provide an overview of studies examining multiomic profiling in various clinical scenarios in the management of inflammatory bowel diseases (IBDs). Recent findings IBD arises as a result of an interplay between genetic, environmental, microbial and immunologic perturbations. The access to high throughput technology as well as the decrease in costs associated with such studies has led to a growing wealth of literature examining the utility of single or multiomic profiles in the management of IBD. Such studies have commonly examined the genome (and less frequently the epigenome), transcriptome, metabolome, proteome and the gut microbial metagenome in the context of overall IBD status or specific clinical scenarios, including the disease progression or response to treatment. The findings have provided important insight into how each of these compartments reflect underlying disease pathophysiologic processes and, in turn, can influence stratification of patients for clinical management. Summary Multiomic profiling in IBD has the potential to advance the field of personalized precision medicine in the management of IBDs.

Original languageEnglish
Pages (from-to)382-387
Number of pages6
JournalCurrent Opinion in Gastroenterology
Volume38
Issue number4
DOIs
Publication statusPublished - 1 Jul 2022

Bibliographical note

Financial support and sponsorship
Ananthakrishnan is supported in part by grants from the National Institutes of Health (R21 DK127227, R01- DK127171),
the Crohn’s and Colitis Foundation and the Chleck Family Foundation.

Publisher Copyright:
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Fingerprint

Dive into the research topics of 'Precision medicine: how multiomics will shape the future of inflammatory bowel disease?'. Together they form a unique fingerprint.

Cite this